NCT03857477View on ClinicalTrials.gov

The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.

Active, not recruitingOBSERVATIONAL
Enrollment

4,700

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

April 1, 2024

Study Completion Date

December 31, 2028

Conditions
Prostate Cancer
Interventions
GENETIC

Genetic SNP profiling

Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.

OTHER

Prostate cancer screening

Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.

PROCEDURE

MRI Scan

MRI scan will be offered to men identified within the top 10% genetic risk score profile.

PROCEDURE

Prostate biopsy

Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.

Trial Locations (1)

SM2 5PT

Institute of Cancer Research and Royal Marsden Hospital, Sutton

All Listed Sponsors
lead

Institute of Cancer Research, United Kingdom

OTHER

NCT03857477 - The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening. | Biotech Hunter | Biotech Hunter